Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01646034 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer

Study acronym: Oligo
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 12, 2022 (before its estimated January 2023 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Site details revisedv13 Show 1 more changeShow less
    • Site details revised
  2. Primary completion date: Oct 2021 to Jan 2023 Completion date: Oct 2023 to Oct 2026v12 Show 1 more changeShow less
    • Completion date: Oct 2023 to Oct 2026
  3. Re-verified, no change to tracked fieldsv11
  4. Primary completion date: Oct 2019 to Oct 2021 Completion date: Oct 2020 to Oct 2023v10 Show 1 more changeShow less
    • Completion date: Oct 2020 to Oct 2023
  5. Primary completion date: Jul 2020 to Oct 2019 Completion date: Jul 2021 to Oct 2020 · Secondary endpoints: 3 to 5v9 Show 2 more changesShow less
    • Completion date: Jul 2021 to Oct 2020
    • Secondary endpoints: 3 to 5

    See this version in full on ClinicalTrials.gov ↗

Show 7 earlier versionsHide 7 earlier versions
  1. Primary completion date: Jul 2018 to Jul 2020 Enrollment target: 86 to 74 · Completion date: Jul 2019 to Jul 2021 · Eligibility criteria shortened, about 27 words · 1 morev8 Show 4 more changesShow less
    • Enrollment target: 86 to 74
    • Completion date: Jul 2019 to Jul 2021
    • Eligibility criteria shortened, about 27 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Jul 2017 to Jul 2018v7
  3. 3 versions Re-verified since Jul 6, 2015, no change to tracked fieldsv4-v6
  4. Start date: Jul 2012 to Sep 2014v3
  5. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study investigates the effect of high-dose alkylating chemotherapy compared with standard chemotherapy as part of a multimodality treatment approach in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency.
Trial Details
NCT Number NCT01646034
Lead Sponsor The Netherlands Cancer Institute
Conditions Breast Cancer
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov